AGP Executive Report
Last update: an hour agoBasilea’s Outlook: The Allschwil drugmaker raised its 2026 operating-profit forecast to CHF 115 million, citing stronger sales of Cresemba and Zevtera, and reported progress on late-stage antibiotic and antifungal trials. Roche Trials: New results point to gains in two areas: its experimental lung-cancer drug divarasib reduced the risk of death by 44% versus current KRAS G12C inhibitors, while sefaxersen cut a key kidney-damage marker by 43.1% in an IgA nephropathy trial. Swiss Innovation: Lausanne-based Sonexos raised €5.4 million to develop technology that reduces low-frequency noise from equipment such as fans and data centres. Research: An ETH Zurich researcher has developed a bacteria-based 3D-printing method, adding a biological twist to the field.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
